Baby dies days after receiving Moderna’s mRNA RSV vaccine

On November 12, researcher Jessica Rose highlighted a U.S. safety report on the death of a three-month-old boy a few days after he was given mRESVIA, Moderna’s newest mRNA RSV vaccine.

The Vaccine Adverse Event Reporting System entry, VAERS ID 2880791, says the infant got mRESVIA on December 1, 2025, at a private facility in Texas. It describes a baby who “was lethargic, had difficulty staying awake, [and had] low grade fever.” The outcomes listed are death and sudden infant death syndrome, and the report states: “Baby passed of SIDS around 2AM on December 5, 2025.” VAERS received the report on January 6, and the lot number is unknown.

VAERS reports are unverified and, on their own, do not establish that a vaccine caused a death. However, the timeline and the circumstances surrounding how this shot was administered to an infant raise warrants close scrutiny.

See, mRESVIA is not authorized for anyone under 18. The U.S. Food and Drug Administration approved it on May 31, 2024, for adults 60 and older, then expanded that on June 12, 2025, to adults 18 to 59 at increased risk. Health Canada authorizes the same groups.

As reported, British Columbia is using only Moderna’s mRESVIA in its adult RSV program this fall. In April, Canada’s National Advisory Committee on Immunization noted that there’s less safety and effectiveness data for Moderna’s shot than for the protein-based alternatives.

The shot was never meant for babies, and Moderna’s own infant trial showed why.

In July 2024, Moderna paused a Phase 1 infant trial after a safety signal, and the FDA placed it on clinical hold on July 19, 2024. An FDA briefing that December said more vaccinated infants developed severe RSV lower-respiratory infections than infants given a placebo, raising concern about vaccine-associated enhanced respiratory disease.

The FDA label, revised in August of this year, now warns of more severe or hospitalized RSV cases in infants vaccinated at five to seven months of age. Health Canada went further. Its product monograph, updated August 19, says mRESVIA “is contraindicated in children less than two years of age due to an increased risk of severe and/or life-threatening RSV-enhanced respiratory disease reported in infants during a pediatric study.”

This isn’t the first adult RSV vaccine to end up in a baby.

Keep reading

NEW 2026 DATA: Measles Vaccines Now Linked to 1,700% More Deaths than Measles Infection Since 1995

In February 2026, the McCullough Foundation research team published Deaths Following MMR and MMRV Vaccination in the United States, analyzing U.S. death reports submitted to the CDC/FDA Vaccine Adverse Event Reporting System (VAERS) from 1995 to 2025.

Our study identified:

  • 299 U.S. death reports following MMR/MMRV vaccination.
  • 193 reports with identifiable dates since 1995, compared with just 7 CDC-documented measles deaths during that period.
  • 52.8% of reported deaths occurred within 14 days of vaccination.
  • 60.9% involved children under 2 years old.
  • Frequently reported presentations included sudden unexplained death, seizures, cardiac arrest, and encephalitis.

The 2026 Update

We have now updated our historical comparison to incorporate newly reported 2026 figures.

From 1995 to 2026:

MMR/MMRV: 198 U.S. VAERS death reports with identifiable dates

Measles infection: 11 CDC-counted deaths

That represents 1,700% more deaths following measles vaccination than CDC-counted measles deaths since 1995.

Keep reading

‘Risk Far Exceeds the Benefit’: Experts Call for Suspension of Moderna’s mRNA Flu Shot After Reports of Serious Injuries

Within three months of the U.S. Food and Drug Administration’s approval of mFLUSIVA, Moderna’s new mRNA flu vaccine, federal health officials received dozens of adverse event reports, including reports of serious medical events that some experts say raise safety concerns.

An analysis of the Vaccine Adverse Event Reporting System (VAERS) database, managed jointly by the FDA and Centers for Disease Control and Prevention (CDC), identified 78 reports involving mFLUSIVA in September and October.

The data, accurate as of Oct. 30, show that two reports were formally classified as serious, while several others described potentially significant medical problems.

Two reports described people who temporarily lost the ability to walk. One, a 71-year-old man, was flagged for a disability less than a day after vaccination when he experienced shaking arms and leg weakness that left him unable to walk.

In another report, an 84-year-old woman temporarily lost the ability to walk within an hour of vaccination. The woman reported severe weakness and being unable to stand, but the report was not formally classified as serious.

Her initial VAERS report listed her as age 71, but an updated version of the report in VAERS’ raw dataset lists her age as 84.

Other reports described a patient of unknown age hospitalized with fever and low oxygen levels, and a 76-year-old man who reported hallucinations after receiving mFLUSIVA and Moderna’s Spikevax COVID-19 shot.

“There are an alarming number of severe systemic reactions, including high fevers, debilitating fatigue and severe body aches and exhaustion” and a “highly concerning” number of cardiovascular adverse reactions,” said internal medicine physician Dr. Clayton J. Baker.

“This suggests significant systemic toxicity very much akin to the disease the shot is supposedly designed to prevent,” Baker said.

An analysis by The Defender found that, among 58 reports that included information on when symptoms began, 51 indicated that the reactions appeared on the day of vaccination or the following day. Baker said that “from a temporal standpoint, this strongly implicates the shots” as the likely cause of those injuries.

The Defender’s analysis also showed that 37 of the 78 reports noted that the individual received a COVID-19 vaccine around the same time they received Moderna’s mFLUSIVA shot.

Of those, 30 reports indicated that both shots were administered on the same day, while seven described vaccinations on different dates. Two reports also listed an RSV vaccine.

Keep reading

‘Seismic Shift’: Medicare to Reimburse Doctors for Diagnosing, Treating Vaccine Injuries

Medicare will reimburse doctors for the cost of diagnosing and treating suspected vaccine-related adverse effects, according to a new Centers for Medicare & Medicaid Services (CMS) policy announced last week and published today in the Federal Register.

Under the rule, CMS will introduce billing code G0576 to reimburse physicians and other eligible Medicare providers for every 15 minutes of qualifying work evaluating, diagnosing, treating or counseling patients with suspected vaccine-related adverse reactions.

The reimbursement payment will be in addition to what Medicare already pays for a standard office visit.

Doctors can qualify for reimbursement by documenting when the suspected adverse reaction occurred in relation to vaccination, evaluating other possible causes of the patient’s symptoms and maintaining supporting medical records.

A CMS spokesperson told The Defender that reimbursement would not depend on a final determination that a vaccine caused the reported symptoms.

“Physicians will not be paid based on whether a report is ultimately determined to be related to a vaccine, nor would reimbursement change the standard for evaluating those reports,” the spokesperson said.

CMS framed the new code as a way to support the Trump administration’s Make America Healthy Again (MAHA) initiative.

“Medicare should reward clinicians for keeping people healthy,” U.S. Health Secretary Robert F. Kennedy Jr. said in a statement.

Last month, the U.S. Department of Health and Human Services (HHS) referenced the initiative when it launched a federal Vaccine Injury Center. At the time, HHS officials said doctors would be reimbursed for time spent reporting suspected vaccine injuries to the Vaccine Adverse Event Reporting System (VAERS).

However, the final rule does not explicitly authorize or exclude reimbursement for submitting VAERS reports, leaving it unclear whether physicians can bill for time spent completing and submitting the reports.

CMS did not answer a follow-up request by press time seeking clarification on whether G0576 covers the time spent completing and submitting VAERS reports.

The code, which will also apply to telehealth visits, takes effect Jan. 1, 2027.

Keep reading

Infant Vaccination Increases Death Risk by Up to 112% vs Unvaxxed

A new study by Drs. Karl Jablonowski and Brian Hooker of Children’s Health Defense titled Increased Mortality Associated with 2-Month Old Infant Vaccinations, analyzed linked Louisiana Department of Health immunization and death registry data to evaluate whether routine two-month infant vaccinations (administered at 60–90 days of life) are associated with mortality in the subsequent month (90–120 days)

Using individual-level records from 1,225 infants who later died before age three, investigators compared infants vaccinated in the two-month window with those unvaccinated during the same period, while holding age-at-death constant.

Infants vaccinated at two months showed consistently higher odds of death in the following month, with statistically significant risk increases spanning individual vaccines, cumulative exposure, sex, race, and combination products.

Most alarming, infants who received all six recommended two-month vaccines had a 68 percent higher odds of death overall (OR = 1.68; p = 0.0043), with the risk surging to +68 percent in Black infants and +112 percent in female infants (OR = 2.12; p = 0.0083).

Mortality risk increased with cumulative vaccine exposure (dose–response)

A clear cumulative risk pattern emerged as more vaccines were administered at the 2-month visit:

  • All five 2-month vaccines (DTaP, rotavirus, HIB, polio, and pneumococcal vaccines) compared to unvaccinated infants:
    +60 percent (OR = 1.60; p = 0.0084 — statistically significant)
  • All six recommended vaccines (DTaP, rotavirus, HIB, polio, pneumococcal, and HepB vaccines) compared to unvaccinated infants:
    +68 percent (OR = 1.68; p = 0.0043 — statistically significant)

Subgroup analyses also showed even stronger cumulative effects:

  • Black infants (6 vaccines): +68 percent (OR = 1.68; p = 0.0311 — statistically significant)
  • Female infants (6 vaccines): +112 percent (OR = 2.12; p = 0.0083 — statistically significant)

This cumulative analysis—summarized in the paper’s abstract and Figure 6—represents one of the study’s central findings.

Keep reading

Pfizer COVID-19 Shot Recipients Show Higher Death Risk Than Moderna Counterpart

A major new peer-reviewed study from Florida has found a significant difference in mortality outcomes between two major COVID-19 shots. Adults who received the Pfizer-BioNTech (BNT162b2) shot showed a higher risk of death from any cause over 12 months compared to those who received the Moderna (mRNA-1273) shot.

The study tracked nearly two million Florida adults who received their first dose of either the Pfizer or Moderna vaccine between December 2020 and August 2021. Researchers compared mortality outcomes over the following year, matching participants by age, sex, race, ethnicity, vaccination month, vaccination site type, and neighborhood.

A stark pattern emerged, showing a disparity most severe among patients 60 and older. The Pfizer cohort experienced 784 deaths per 100,000 compared to 562 among Moderna recipients, a 40% higher risk. The analysis also showed particularly alarming gaps in cardiovascular fatalities (up 57%) and COVID-19-related deaths (up 91%), while non-COVID mortality was also significantly elevated at 37% higher.

The Gateway Pundit spoke to Nicholas Hulscher—an Epidemiologist and Administrator at the McCullough Foundation—expanded on the study’s findings.

First, applying the study’s 40 percent higher all-cause mortality hazard to an assumed 150 million U.S. Pfizer recipients and a baseline annual mortality rate of 0.87 percent, he calculated 522,000 potential excess deaths.

“That’s a hypothetical extrapolation of over half a million excess deaths from Pfizer alone,” he explained.

Hulscher then offered a more conservative estimate using the study’s absolute mortality difference: 221 additional deaths per 100,000 Pfizer recipients. This calculation yielded “331,500 additional deaths—if what we saw in Florida holds nationwide.”

Keep reading

VAERS and VSAFE: The “Worst Case Scenario” Twice

Files that were removed from the internet are in the evidence pack.

The scale of the violation is hard to imagine, I know. After the dazed feeling wears off, let’s get busy. I also want to thank Dr. Clayton Baker, who was the first to bring my attention to the role of Tom Shimabukuro in covering up vaccine safety signals for over ten years. Incredibly, he is still at the CDC, serving as the deputy director of the Influenza Division in their National Center for Immunization and Respiratory Diseases (NCIRD).

The following research brief benefited from various digital research assistants, and I have not edited the language yet. But the information cannot wait.

Read and share with friends and family. It’s not over yet.

The United States began vaccinating against Covid-19 on 14 December 2020. Two CDC programs were designed and paid to catch any harm that clinical trials had missed. VAERS takes reports from doctors, patients and manufacturers. V-safe sends vaccinated people text messages asking how they feel. Here we follow the paper trail of those two systems from the Christmas 2020 rollout into 2022. The bottom line:

The government’s “worst case” for amount of Covid vaccine injury reports assumed 1,000 reports a day. For fourteen months it was double that. For some of those months, it was triple.

The document that matters most is a monthly report from the contractor that runs VAERS for the CDC, General Dynamics Information Technology (GDIT). It covers December 2020 and went to the CDC’s contracting officer’s representative on 16 January 2021, with CDC program staff and an FDA reviewer copied. Its first page carries a chart.

A red line marks 1,000 reports a day, which the government’s own planning called the “worst case.” The reports crossed that line on 21 December, the winter solstice, in the first week of the rollout. They dipped under it for three days around Christmas. From 26 December they stayed over it. The contractor told the CDC. that it was “unable to meet processing and other timeframes (data processing, telephone inquiries, clinical inquiries, etc.)” (GDIT report, PDF p. 8). All this while they were telling everyone everything was ok.

Keep reading

FDA Official Urged Fatal Myocarditis Warning on COVID Vaccine Labels 10 Months Ago. It Was Never Added.

A U.S. Food and Drug Administration (FDA) safety official recommended adding a warning about fatal myocarditis to mRNA COVID-19 vaccine labels in December 2025, after an agency review identified several pediatric deaths as possibly or probably related to vaccination.

More than 10 months later, the agency hasn’t added the warning.

According to documents obtained by investigative journalist Paul D. Thacker, an FDA pharmacovigilance expert — Dr. Meghna Alimchandani — emailed agency leadership on Dec. 5, 2025, formally recommending that a warning for fatal myocarditis be added to mRNA COVID-19 vaccine labels.

Her recommendation followed an internal memo from Dr. Vinay Prasad, then-head of the FDA Center for Biologics Evaluation and Research (CBER). The memo, later leaked to The New York Times, revealed that agency researchers had initially identified “no fewer than 10” child or teen deaths tied to vaccine-induced myocarditis.

However, documents released in June by Sen. Ron Johnson (R-Wis.) showed that a month after CBER identified the 10 child deaths, it reduced the number of deaths to seven and downgraded the probability that the vaccines were directly responsible.

Several former FDA officials told RealClearInvestigations that the leaked memos and documents — along with reporting by The New York Times and other news outlets — “appears to have unsettled the FDA’s safety office,” leading the agency to reduce the number of child deaths that it linked to the COVID-19 shots.

In May 2025, the FDA directed Pfizer and Moderna to strengthen their COVID-19 vaccine label warnings by expanding the age group at risk for vaccine-related myocarditis and pericarditis and warning that myocardial injury can be lasting — but the warning about fatal outcomes has never been added.

Thacker suggested that overlapping political, pharmaceutical and media interests may have led to the FDA decision not to add the warning.

He attributed the lack of action partly to the Trump administration’s investment in Operation Warp Speed, which accelerated vaccine development in 2020, and to what he describes as the Biden administration’s reluctance to publicize findings that could undermine its vaccination policies.

Drug safety advocate Kim Witczak, a former member of the FDA Psychopharmacologic Drugs Advisory Committee, told The Defender that the warning label issue should not be partisan.

“This isn’t about Republicans or Democrats, Trump, Biden or RFK Jr., it’s about the American public’s right to know,” Witczak said. “If FDA scientists identified credible evidence of fatal myocarditis and recommended updating the COVID vaccine labels, why hasn’t that happened? Who made that decision?”

Keep reading

CDC Death Certificate Codes Show ‘Robust Safety Signal’ for COVID Vaccines

The number of U.S. death certificates listing Y59.0, the code for a death caused by a viral vaccine, rose from fewer than 10 per year through 2020, to 198 in 2021, the year COVID-19 vaccines rolled out, according to a new analysis of CDC data by the research group CORRELATION.

Researchers said the significant increase in certified vaccine deaths starting in 2021 is “unprecedented,” at least since 1968, and constitutes “a robust safety signal for COVID-19 vaccines.”

“Our results show that exceptional and brave attending physicians reported COVID-19 vaccine-caused deaths on the death certificates that they were legally mandated to complete, despite the large professional, institutional and political bias against doing so, and that these death-certificate results constitute a significant safety signal unprecedented since at least 1968,” Denis Rancourt, Ph.D., lead author of the analysis, told The Defender.

He added:

“There is no justification for a claim that the COVID-19 vaccines are ‘safe,’ since they caused certified deaths, beyond any previous levels for any vaccine type. The side effect of death must be mentioned when informing patients. There is a definite lower-bound risk of death that cannot be argued away by health agencies.”

Keep reading

EXPOSED: The Scale of Corruption In The Vaccine Industrial Complex

For decades, the public was told that pharmaceutical products undergo the gold standard of scientific scrutiny: randomized, inert-placebo-controlled clinical trials.

But as Bret Weinstein and Brownstone Institute’s Jeffrey Tucker expose, the reality behind vaccine approval is pure regulatory sleight of hand. New shots are routinely tested not against a true, inert saline control, but against earlier vaccine versions or active adjuvant concoctions, falsely labeling them as “placebos.”

Under this rigged framework, as long as a new shot causes no more immediate harm than the last hazardous formulation, regulators stamp it “safe.”

Combine this rigged safety baseline with statistical tricks that inflate tiny, meaningless results into “95% effectiveness,” and the entire corporate narrative falls apart.

The system was never designed to uncover true harm; it was designed to hide it in plain sight.

You will not believe how corrupt the FDA’s process for vaccine safety testing is.

“It’s just smoke and mirrors.”

Send this to someone who still believes Pharma’s “safe and effective” narrative.

New vaccines are never tested against a placebo.

Bret Weinstein: “That’s jaw-dropping in and of itself.”

But it gets worse.

“They test it against something that they claim is a placebo… the last version of the shot.”

“If the last version of the shot was demonstrated to be safe, and the new version of the shot doesn’t do any more harm than the last version, then it’s safe, right?”

Jeffrey Tucker: “If it’s slightly better, then you report the relative efficacy.”

“It’s a tenth of a percent, and that’s where you get your 95% effectiveness.”

Keep reading